<SEC-DOCUMENT>0000950170-25-058776.txt : 20250425
<SEC-HEADER>0000950170-25-058776.hdr.sgml : 20250425
<ACCEPTANCE-DATETIME>20250425163011
ACCESSION NUMBER:		0000950170-25-058776
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250425
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250425
DATE AS OF CHANGE:		20250425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prelude Therapeutics Inc
		CENTRAL INDEX KEY:			0001678660
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811384762
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39527
		FILM NUMBER:		25874577

	BUSINESS ADDRESS:	
		STREET 1:		175 INNOVATION BOULEVARD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805
		BUSINESS PHONE:		(302) 467-1280

	MAIL ADDRESS:	
		STREET 1:		175 INNOVATION BOULEVARD
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19805

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prelude Therapeutics Inc.
		DATE OF NAME CHANGE:	20160630
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prld-20250425.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-04-25T11:53:13.6185+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:prld="http://preludetx.com/20250425" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_0325dad3-95b5-4fa8-b066-8c4d995b932b" name="dei:EntityCentralIndexKey" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f">0001678660</ix:nonNumeric><ix:nonNumeric id="F_b11df8ad-c592-45a1-bee3-3da781279d2d" name="dei:AmendmentFlag" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="prld-20250425.xsd"/></ix:references><ix:resources><xbrli:context id="C_c97c737f-60b2-470b-90be-d8360453916f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001678660</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-25</xbrli:startDate><xbrli:endDate>2025-04-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96db1804-329e-4d16-8b12-58bb550030dd" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of The Securities Exchange Act of 1934</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08b7b43c-87f2-467f-a5d7-8fd83c6f744f" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 25, 2025</span></ix:nonNumeric></span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da046754-b8a1-4009-9b52-c2e06084daad" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude Therapeutics Incorporated</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p><p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:31.973%;box-sizing:content-box;"/>
     <td style="width:1.983%;box-sizing:content-box;"/>
     <td style="width:14.981%;box-sizing:content-box;"/>
     <td style="width:1.983%;box-sizing:content-box;"/>
     <td style="width:14.981%;box-sizing:content-box;"/>
     <td style="width:1.983%;box-sizing:content-box;"/>
     <td style="width:32.117%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_17e7df35-a892-42f0-b49f-a1ead193cdae" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5e64dcd5-2ebd-488c-9b57-aaf24f90afdf" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-39527</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_243984f0-7050-46c2-9e58-016cd0128f6a" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81-1384762</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of<br/>incorporation or organization)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission<br/>File Number)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8891dda9-f4eb-466d-ae3c-6a0356c83791" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">175 Innovation Boulevard</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_48e3f4ae-31eb-4ce7-b2e1-23d52707d4cb" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Wilmington</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_1d31282e-e610-4e3e-97d1-3bd681abf181" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b67f5362-ad19-402e-b19c-5a1c0fbeb8ca" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19805</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63ddecb7-79b9-4553-85d1-c558d217ff9b" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(302)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78e721b3-20aa-4fbf-b82b-9c1e6e242408" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">467-1280</span></ix:nonNumeric></span></p><p style="margin-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_9f294cbf-10d1-4450-99dc-1a267fa31fbc" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_603c03df-0afb-4ec8-a22c-08f8a195b6bd" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e15ddfe4-280a-4df9-bcf5-c15c590e6095" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b0531577-b943-4b40-93b0-744d71d81e60" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:41.02%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:14.96%;box-sizing:content-box;"/>
     <td style="width:1.98%;box-sizing:content-box;"/>
     <td style="width:40.04%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #ffffff;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2a39a9eb-1130-4322-84ef-8e20927ed53b" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7da9fe58-dfba-42d6-923d-5528018e6a8f" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PRLD</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_83c447bd-f446-43a9-86e7-67f9992a1afb" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_75e620ca-071a-46f7-81b1-641ff3a79a73" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c54dcab9-7b9f-4440-bb3b-c5da88916aff" contextRef="C_c97c737f-60b2-470b-90be-d8360453916f" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other events</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 25, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective IV SMARCA2 degrader and its highly selective KAT6A degraders. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:2.96%;box-sizing:content-box;"/>
     <td style="width:87.04%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="prld-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.14%;box-sizing:content-box;"/>
     <td style="width:4.1%;box-sizing:content-box;"/>
     <td style="width:45.76%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PRELUDE THERAPEUTICS INCORPORATED</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: April 25, 2025</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Bryant Lim</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bryant Lim</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Legal Officer, Corporate Secretary, and Chief Financial Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prld-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img268059179_0.jpg" alt="img268059179_0.jpg" style="width:261px;height:97px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude Announces Presentations at 2025 AACR Annual Meeting</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical data elucidating the mechanism of action of PRT3789, Prelude&#x2019;s first-in-class, highly selective SMARCA2 degrader currently in early clinical development</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Highlights from Prelude&#x2019;s efforts to discover and develop selective KAT6A degraders, including preclinical data, demonstrating potential for a differentiated efficacy and safety profile</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WILMINGTON, Del.,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Apr. 25, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(GLOBE NEWSWIRE) &#x2013; Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting for its highly selective IV SMARCA2 degrader and its highly selective KAT6A degraders.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, &#x201c;We are pleased to provide further preclinical data on the discovery of our lead selective SMARCA2 degrader PRT3789, currently advancing in early clinical development for patients with SMARCA4 mutated cancers. We are also delighted to report initial preclinical data from our selective KAT6A degrader discovery program. These data demonstrate that selectively degrading KAT6A results in robust anti-cancer activity in various pre-clinical models of breast cancer and other solid tumors. We believe that our first-in-class, highly potent KAT6A selective degraders have the potential to expand the therapeutic reach of KAT6A/B inhibitors currently advancing in the clinic, while addressing safety challenges associated with non-selective approaches to this clinically validated target.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details on the presentations are as follows:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Elucidating the Molecular Mechanism of Action of the First-in-Human SMARCA2 Selective Degrader PRT3789</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.4671798606054303%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRT3789 is a first-in-human SMARCA2 degrader that selectively induces deep and sustained SMARCA2 degradation in preclinical and clinical studies.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.4671798606054303%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRT3789 achieves high selectivity by inducing a more stable ternary complex between SMARCA2 and VHL than SMARCA4 and VHL.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.4671798606054303%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">K1405 loop in SMARCA2 provides a unique lysine residue to enable selective ubiquitination and also stabilizes the SMARCA2:PRT3789:VHL complex.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.4671798606054303%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4 thereby enhancing the selectivity profile and contributing to the broad therapeutic index and favorable safety profile observed with PRT3789 in clinical studies to date.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.4671798606054303%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRT3789 is currently under evaluation in Phase 1 and Phase 2 studies in patients with advanced solid tumors with loss of SMARCA4 (NCT05639751 and NCT06682806).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Link:  </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publications - Prelude Therapeutics (preludetx.com)</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title: Discovery of First-in-Class Potent and Selective Oral Degraders of KAT6A that Demonstrate Anti-cancer Activity in Pre-clinical Models</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KAT6A expression is associated with cancer growth and is recurrently amplified in breast, lung, ovarian and other cancers.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KAT6 is a clinically validated target with a dual KAT6A/B inhibitor recently demonstrating promising efficacy in heavily pre-treated patients with ER+/HER2- breast cancer, albeit with potential on-target safety considerations including neutropenia.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude hypothesized that a targeted protein degradation approach could enable discovery of KAT6A selective candidates with potential for improved hematological safety and more robust single agent activity relative to other KAT6-targeted approaches.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude believes that it has identified a series of first-in-class, sub-nanomolar, selective and readily orally bioavailable KAT6A degraders now advancing to candidate nomination.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-clinical data presented demonstrate that Prelude&#x2019;s selective KAT6A degraders: </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drive significantly deeper anti-cancer responses compared to non-selective KAT6A/B inhibitors across multiple KAT6A-amplified tumors. </font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disrupt the histone acetyltransferase (HAT) complex resulting in a deeper biological effect on ER&#x3b1; expression.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Show sustained activity in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ESR1-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pi3Kalpha-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mutated cells, as well as endocrine therapy- and CDK4/6i-resistant cells.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit robust combination benefit with SoC and potential synergy with next generation breast cancer therapies.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deliver robust </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> target engagement and deep tumor regressions, including complete regressions, in breast and lung cancer xenografts as a monotherapy at low oral daily doses.</font></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Display reduced hematologic toxicity compared to KAT6A/B inhibitors.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Link:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Publications - Prelude Therapeutics (preludetx.com)</font></font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">White J, et al., Histone lysine acetyltranferase inhibitors: an emerging class of drugs for cancer therapy. Trends Pharmacol Sci 45 (3): 243-254 (2024). </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sharma S, et al., Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. Cell Chem Biol 30 (10):1191- 1210 (2023).</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">About Prelude Therapeutics</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders, and ongoing research into other precision oncology targets. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events &amp; Presentations - Prelude Therapeutics</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For more information, visit preludetx.com.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the &#34;safe harbor&#34; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude&#x2019;s product candidates, and the potential safety, efficacy, benefits and addressable market for Prelude&#x2019;s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;estimates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;could,&#x201d; &#x201c;should,&#x201d; &#x201c;potential,&#x201d; &#x201c;likely,&#x201d; &#x201c;projects,&#x201d; &#x201c;continue,&#x201d; &#x201c;will,&#x201d; &#x201c;schedule,&#x201d; and &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company&#x2019;s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude&#x2019;s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading &#34;Risk Factors&#34; in Prelude&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> <br>Robert A. Doody, Jr.<br>Senior Vice President, Investor Relations</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prelude Therapeutics Incorporated</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">484.639.7235</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rdoody@preludetx.com</font></font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img268059179_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img268059179_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A 04# 2(  A$! Q$!_\0
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M:U[7VO;6V]M=CIZVZVO;K;:_I?0LT444 %%%% !1110 4444 %%%% !1110
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M[3Q%#=Q*UKM9?E'_ (*CZE^QG_P]A\ Z7^WY\5O%/PQ_9]/[%9O=,N=&\?\
MQ2\$V-Y\2&^*&IPZ3%,WPPF&IW4SZ.=6(6>$6I$*-/+F*&,_KOK/_!,3X)^$
M_C_^SE^T5^RSH?@;]EGQA\%/$/B2'QMI?PR^'FA:3X>^-GPP\9Z2FF^(_A_X
MST[1VT>#SHIH+;4_#GB%H[N[T6_C9UAGB*1Q^E>(/V)-"\4_MVZ1^V?K_B#3
M=9L],_9SNO@&?A;K7A+3-7TZ1[CQD/%R>+DUF_EG:&Z@(.GK9QZ<-T3O)]J
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M+%C9"_O;J]%E90^&_";Q65D+F:46EG$7<Q6ML(X(RQV1KDY^(OV0OV5/"/\
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>prld-20250425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-04-25T11:53:13.8001+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://preludetx.com/20250425" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:prld="http://preludetx.com/20250425" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:roleRef roleURI="http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="prld-20250425.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_FormerAddressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former Address</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_FormerAddressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Address [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain" xlink:to="dei_FormerAddressMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_FormerAddressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
        </link:definitionLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Prelude Therapeutics Incorporated<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001678660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1384762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">175 Innovation Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">467-1280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRLD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,6#F5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,6#F5K9=+P\\0   "L"   1
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MMA&P\G^?-NL9!)EVZ<?]!9M+&]6F7X.(&V&^$5#!VQG[T;MPFS*6"LTV(LJ
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #%@YE:99!YDAD!  #/ P  $P
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MPP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Q8.96IE<G",0!@
MG"<  !,              ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #%@YE:I8:(56\$  !,$0  &               @($D"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Q8.96I^@&_"Q @
MX@P   T              ( !R0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #%@YE:EXJ[',     3 @  "P              @ &E#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #%@YE:'#AEZC\!   \ @  #P              @ &.
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Q8.96B0>FZ*M    ^ $
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ Q8.96F60>9(9 0  SP,  !,              ( !WQ(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  *10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="prld-20250425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="prld-20250425.htm">prld-20250425.htm</File>
    <File>prld-20250425.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "prld-20250425.htm": {
   "nsprefix": "prld",
   "nsuri": "http://preludetx.com/20250425",
   "dts": {
    "inline": {
     "local": [
      "prld-20250425.htm"
     ]
    },
    "schema": {
     "local": [
      "prld-20250425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c97c737f-60b2-470b-90be-d8360453916f",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prld-20250425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c97c737f-60b2-470b-90be-d8360453916f",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prld-20250425.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information:",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "terseLabel": "Document Information",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Address",
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://preludetx.com/20250425/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-058776-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-058776-xbrl.zip
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ME_FD&R>2*\EYZW4'Z!;T/PSX6<K1MQX:3$= W1]V<IKD. <A%MYXHDFH>V8
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MPEODC]R/M52813]$B ]!5"G="*(J2560PSCG*A5T?!:'+B\^5W<&H_*Z8TE
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M-[ ]%$08@C>WG]^"/_]Q<PUN[7NXL, %LJ,%]$-@@/LP7!Z;YN/CX]"9N7Z
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M(-U".\*$B/%D>D<W=0FL0I&VQMKSOGPAV/G9\58HTQ(XZE<E:T72_&?!L,_
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M4 ;H20F<;4DR>_7[LG"&G&?EPPM<K[5).\N>(BED\/<4YWTNQH!<EP'@:B1
M(9FT3EL-=C*18@17)0I3($6Q]RA+ 4"C\N+0NP$C1V1N>,0/CCX(QC7@8B2X
M0;Q4*&U-)5""4:8!\_0R2@+F(4KF(N(,VU>99M!$>)_24RA0<^V'AU/ 7\30
M>_4@PM\4D!Z^&W8C[<2WOL/BC";$ J(#IL7\A'AD0(H5).^Z>6F!MC[H2)+T
MN30MDHEQ'G<A?&G&L$9P+6XAN33"O3\7<P6L#]"MHAV8E6L#)^K:!-*713 7
MF+96P\Q8H#I6-MTL2.F<2DO:X91KJ3*#XVT6 XX53,W@P@\U;)QE^8M NA3M
MFE&1A&EGL?*+,H2U@!5U0\-IWJ&U.OG<#W.^% 758Q-.K8B2) ^K*VY3[!RO
MVSD+@7ER(,HP3FKO^:\P([+]P:CN @-LPDVTP0"E(MC+,(3U,GC?:P2@H$>1
M2,: /]PS!-AD @Q G.9\V#R%K8(A"-)J[$2: L"@WRF@=DBO6D!\85L.*\)-
M%J2_*Z7A"[7E]2W%J;!<(D8E2Z*)<?0$E&851>K&]!_#@CU)\>+!H>0*#YGZ
M[&S!8/A6 ;G)(JY!WBR9#@>%Z1 ?^BTGMR\SZ+3@CI<%J3I=X),U#7IBT'69
MQ3#T6?]+U(H''V2%$)3.Z6! <3.2 .( T"BST:#2TE%=U2I[L/_C$<A3:<1G
M_5$D;JO;^Q$D(CF:Y?W2$ZAE:GM$&]G$[DQ_"#(K<'.QM.7ST7O[[\:0U5YK
M9V^_LW]XL-?>:^_N]-HPN!NEPR8*<M?]:R%2&&=4K(U,<()-6J)[5@41"427
M;K= I=)QM>NYTV[_N-#LIG 73_$82&=\+I=.*H2RD,*79&N9A!F>#8:P=LYL
M#.N$Q\3APLO.:@ B9EGVQQ>*'\9FH11SS9Y.I/W_-;#7P+Y.8 >M!!4R9V<J
M !JUOJ&':90O..AZ('["Q(>@"5GH %@$V=5@/4"ILS="S)$$@?GWEV\01Y)"
M1?875P)UQ>5BP:>B>T1K'DHM2)+IPXIE<5*%Y-P5)H=&\H99\(%9N94B"3?%
M.68=$M#/@]0J\V@/,_YBN@>+L[WB$^AF;=,MP'"B%RBH)PF$^.2S=52] 6#D
M+J=\+!Q=:?(1X$F?1S=\9FKGK4?KO%4SW)KAK@-B7W=VVKLL4BI%V2]GE=[,
MC1)GEL@_,L&BF8%1HVE6AO 3C9H)<=VY.3$;PI, J8D3)9&SDJ$9V;.,8-R&
M='W?1]^S^CZR9,^R:]&RAO0'@_0<M@&$9PD H@&%BLXCX+/;[#%++9M(W3@]
M:BXCHLU>@-PIDHFWQ",<EX52[X3C]"7H4<MAYBQ@BIX=:L7#BNV?B#L]/^)3
MI1TJ53QZF!J"[##-3?>%&I@L:63DDP0SJ=&G1I^O88:8GTUE"1H=Q)1'66$_
M.)_ CK,.P;;[WBT %<T+E9-*=[@%,%X^DG.W(F7H$"_'PJUW)U?MW;W>X?ZN
M:QQ_[^T== _:>]LK07_#](3ORC#\E.:Z,?;E-S*Y[K.*T]2WVI7S;!@!#W)G
M@,W5'E);J;MJ;UL@X&T76UA#[9."6G\P>%IVB2D._$Y0-&'GSJ\"J?K\S.^]
M!A'GM'"MR/TDG(W[M.10,BAYAPQ*WB'G9:^0M^05\GB.CVK4^/:H\="'F%]X
M3$A2\Q,5T'?V#SN'G9W=3ALEPEH^?^%HH[A-R1L,1?%E]R]/(\=:W:#LC:Z\
MH .+DJ]9G$9R).%Y()_.>Z[!HBP9-YA"7SN>E+SH<J_"SZ2IP HL.4@[B#(9
M 'K9JMYJ[[1+?YVUK51GS6IRC88U&E;0T!W5W^-*Z75?%J(;_I+S)V*D0\>%
MX#"M8DF.GD4<&&#I1/"I1-=4F):%A<=>JCKVV<4_G[\\N^@VJ_ZP#<:CH9!^
M,'-_506 ZT:9^Y/"&"2(8%[8GT>S)2#G:Y6*1/)'1P2Z-1&HB<"#*<=>&Y[,
M4D66YC\IJ@?4%NXI "*I!I0#!"Z[W^0>V8!S613F1RR58()%WW- YI"(BUE$
M9(KKB?$H!WJ;B)A;C#MRAF.'V<C+R8/"N]DC<4$K]IB4L5R3RH\=T<SL.#^.
MH5E,9.Y&OFX#=(U4-5(M(96/U3 .H8!_33@PI=#%]2 X,G2Y$&0P6 SC,-FP
MF?!$Q2KBP !+H1" ";"V(7)2I8EI#Z7B4RXC0L&%Z#:6J)M28 8@1H&&<"OV
M1Z U.M3H\)#HT*S&:/FX#!$N1ULM93.X,VZSS]8*M)WV4X78_7:O_+>W)I!5
MCQ%63S5"FH%MP=!+[G4;D5)0WMQV"_"; MQ")Q0:K5UH8C5F;46H' \T'A7&
M661EFM/JYMR4D<?YU8!= _:Z 5L:G:4N"G\"H // CB":!T!\4W,")1F(]C6
MR\'5=N&6[*);?3PGS_$ I(U<. ?M'H =H^W.+H!B]X:=HY)=;[U"10W&-1@_
M>W$Y 7%V'AA2CK#^2FD</C-KT]GE1:>Y49DF4)'8[#4[E[W7/$HG?*,6KDA5
M(*((%#50Z6[@&WZ*)%2!1N=3YS\W:](BGYR^WGF^)YOHD6HP2ZE[M2:/-7E<
M-VSF7OW>2@:,?)@[.0]%(D:Y#?U2G1!HSDUP9I8(/9[YY NPNVP,+VC_;B4[
MA0/NM<?7U1!<0S!F<(@D)BST$+S9# KSNLBIVB3NE)_;B63,QX1T/O>C2)UZ
M"5+]V OHE82/3NBW8O%^COS8"IZOYU3@5B28/&=D\?">XAL3Y=D>9ON*0$Y#
M\R0+.5HJ0V5J>E'3BP?1:W%4 +48/5XY/6)6W<I VEG%2+-LEJD]LC?4J>WK
M>"EO%/6N':8?(P+5)V6;<U+6:3U&-O8!>V+_;C 0W7C4:K"7WD;KHUGGIEIO
MJ9VSKSZ(9@Q #3=^[, 0#Y1#G8T->594U+99BUUID80&(YYTS&'"F&N2[>RR
MK=YVGW5W>LWN[@[;ZK:[.]NKCR+J;!-UMHDZVT2=;>+3[5(;G6VB9L5K9L7=
M1\F*+XDOLLLY+Z[$@_%JAMV2:U9CI3_6W%FZE#[WSA-8[QHY+Y\Q!N@W/H]O
MDU),G5W\LVJ0;;$3/( X =67_2J!G_?:;*O3WNYW8$N;K-/MM(F=]^K8X^]1
MT_U,V^5@J#*[4KG;;)OK5PL]]*1M4\C22C6<PC<P87M>LF=UX88\";MSY4C4
MU'E)QR*4 5!>RG; D:0@C2(BDR4Q4+]$B+"L0N31&BWV/H-?,B5.1XD6H",M
M,?4\M&"@-S3]0D<B(D6D[/L]-SG_[8);:'M>JE5$X5W)6&%+.J\;(9/"]7O%
M<CC;^$)V^8A&2\H3YE,7MRE&>I"*=;\+?*F^4J,HKN3RJL2@C@628RJAI<.T
M4H$**ZFZ)6SRQVQ,B[-U7HQZ<'IBMKVG//#3I)P6'QWP62Q=^!RE;0<HR<MQ
M8.R-P'V8KT"^T_0L<;+JCN)<<;/=QA;50JJU/;!NQU  /&28+\ENA*WJ;$K1
M0S_Q.#U:J"JXVG*U8*G:!,QNL=\ Q2BZ02: ;3%-H,&FL'>650QM3[-6R1V4
M^'L5)+Z0\7P#6>($E&D 64QI^@[H)+L08ZZ)Q -DW\#7YANEKO'W)?K.H"Y6
M2QD;*65<86D-<N#$8"HL)L.\"DZV1-K+R.^E*?:2N)2O^1$+GA O=?GR?_JA
MMW.$05P,U*JATO3;9>VC(^;\N7,MI\AQ+C'&&]1Z&/\;^!@[UG,AD"YBR@Q\
MOG-XN%LZNFZP(4BRB;(LDK%T96(:Q%T#F9*K5A&6UK@[9W2Y3HUW*\1!H/2S
M%), PP^SP):D&B>.5,NIN-"U1J',-7(?'.,R#KIR**0D H!<"_MW.VNQ0125
ME]\)/)0)KGQUY/1,3?,;P:1(=B@]01$7+H!OB+5AX')XSS93G1R&I@%3%![*
M8YP:><V5XLY\ U;<% #U\>I;:03:\(HW0"X+[(H;$F$W7'$CYK/EBS3;Y<MF
MLOIZL9O+MR)Y+:(5/<!^?5P]4L0DF61B^<Z-C%;T8(*)"+.H]#S"3?$.CKAR
MQP#X8_F*N0NV*WKB5L@=?_OPL]D]VXSAUA;68SPAI.)1=!_J>_* L(\RLV\>
M'R) R6LKW=,"%:[2**$ZP6U():Q\"9<3I\',T<&G@& .'O+2+@F)Z!^%;X*3
M<CO*; 9M"R<CXC-Y%290-[(XI6<1F?QL5\?MX2@JG6DQ0@7%I9XP&6@=?S$Y
MU*P4!<@658<1FW%QQQG7@"A"5 ?;R"M+-7SE8OB">HHK%I5[/0,U$YH$1I#E
M&99A=;G(\UW,"SD!6& *<@H<=/6JL.*4!- .)HG3C"K4K^(8J,4XBSA0D9D+
MGYW"-8E:W$04J?5 DT 8:!7L_HZ%,-D0MXC*>$ES[?:D>)WH+2TY8"XL4&9$
MOEP_8^R,Q1P$)=),ODQN/J2*80':A= =*@8&NVM$CA1NUU GOG/3REY1=PV3
M3,X.HTI#Q.2Q=H87?;9 *D"XBEO@OF#R!)FZ]?9[A$K;JI4/!<Z+>TC(]\$L
M:9M%$<95?1:LSFIB3Q(53M*B0><KC5TD6@'.8]$UB<PIU_HQ*#5-(RK;)5UZ
M%8"\#!D+L&S4YWF C4CL;(F-E3I "[_-FX!54+!E?[IB9 6'A#GX]:Y,WBT:
MAHD/9W<N[&J OY/STW+,AUS=R%$VKYR\*!L0%W<H5WEDK.YNCPP)@26:'"$9
MR:B(G4*CPZQ1REES%^3!:@1:#D7H4UI20(^W )%P=0$OLM]@F$H;)VVY!&/5
M[?"5-2]<-3T FM]0P.JTFZ])"L%69P)Y"3&.4UCU> B]]3I4D'6G09#]'Z!>
M5F"Y/]>.*3?TG])D0A5D)9$C)X*8/-97L<:<MI2#%C_)Z$$9F.?2(#9V=HMU
MF<;$%;SUXV_P%Y,*?@TCPZQ!A;Q) =#T?5'@=9N0#Y$6V?)K@9'43 VC7"2E
M4H13LK1HEJ74WKUDQ;A7B'?D/ E-:U+#VF!< !8_H5/(^0"1QJH1B)"W@4!*
M88@T#I%V_)%)[= @XC=KL NL+V')@Q;SQ$/E+SQ@6-^QYCUGTK5K1.T:4;M&
MU*X1&^0:\<@./]?'D%XEH,SA"?P)+EE@U^#RNT9N>3S4+RX4"%>6#5KL5*D0
MY,!_ZQ9>OQ2)A''_+@-2A0RIUPU63.B"MA?DXL=PR+WNE5MY(EJN=;]9V_P$
M=VCG8*>UUSML[7=[N]]&)OPT(61],]<AXO%_5P[O5CC)U^)B+2Y^_^+B\7-T
M<WCQC^/G$QM'+_X?4$L! A0#%     @ Q8.96J,&DK8N$P  0L<  !$
M         ( !     '!R;&0M,C R-3 T,C4N:'1M4$L! A0#%     @ Q8.9
M6B)Y_\9:#0  4,0  !$              ( !71,  '!R;&0M,C R-3 T,C4N
M>'-D4$L! A0#%     @ Q8.96N7;TE$N$P  !90   \              ( !
IYB   '!R;&0M97@Y.5\Q+FAT;5!+!08      P # +L   !!-      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>prld-20250425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prld-20250425.xsd" xlink:type="simple"/>
    <context id="C_c97c737f-60b2-470b-90be-d8360453916f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001678660</identifier>
        </entity>
        <period>
            <startDate>2025-04-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_0325dad3-95b5-4fa8-b066-8c4d995b932b">0001678660</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_b11df8ad-c592-45a1-bee3-3da781279d2d">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_96db1804-329e-4d16-8b12-58bb550030dd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_08b7b43c-87f2-467f-a5d7-8fd83c6f744f">2025-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_da046754-b8a1-4009-9b52-c2e06084daad">Prelude Therapeutics Incorporated</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_17e7df35-a892-42f0-b49f-a1ead193cdae">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_5e64dcd5-2ebd-488c-9b57-aaf24f90afdf">001-39527</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_243984f0-7050-46c2-9e58-016cd0128f6a">81-1384762</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_8891dda9-f4eb-466d-ae3c-6a0356c83791">175 Innovation Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_48e3f4ae-31eb-4ce7-b2e1-23d52707d4cb">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_1d31282e-e610-4e3e-97d1-3bd681abf181">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_b67f5362-ad19-402e-b19c-5a1c0fbeb8ca">19805</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_63ddecb7-79b9-4553-85d1-c558d217ff9b">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_78e721b3-20aa-4fbf-b82b-9c1e6e242408">467-1280</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_9f294cbf-10d1-4450-99dc-1a267fa31fbc">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_603c03df-0afb-4ec8-a22c-08f8a195b6bd">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_e15ddfe4-280a-4df9-bcf5-c15c590e6095">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_b0531577-b943-4b40-93b0-744d71d81e60">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_2a39a9eb-1130-4322-84ef-8e20927ed53b">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_7da9fe58-dfba-42d6-923d-5528018e6a8f">PRLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_83c447bd-f446-43a9-86e7-67f9992a1afb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_75e620ca-071a-46f7-81b1-641ff3a79a73">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c97c737f-60b2-470b-90be-d8360453916f"
      id="F_c54dcab9-7b9f-4440-bb3b-c5da88916aff">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
